Genotype, Phenotype, and Disease Progression of Developmental Epileptic Encephalopathy With Onset Before 2 Years of Age

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-02-27

Study Completion Date

2028-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

According to estimates by the World Health Organization in 2019, more than 50 million people around the world have epilepsy. Nearly 80% of patients with epilepsy live in developing countries. Among them, children under 2 years old are the group with the highest incidence of epilepsy, and at the same time, the most dangerous epilepsy groups are also likely to start at these ages. World medical literature on epileptic encephalopathy and early-onset development before 2 years of age records that 71% of children have severe intellectual disability and 60% of children show signs of autism spectrum disorder, of which Children with epileptic and developmental encephalopathy due to genetic causes are at higher risk of developing neurodevelopmental disorders than children with epileptic and developmental encephalopathy due to other causes. However, in Vietnam, there is no research on this topic.

The question is what are the phenotypes, genotypes, and progression after 2 years of follow-up of Vietnamese children with epileptic and developmental encephalopathy with onset before 2 years of age?

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical-genetic Investigations in Children With Early Infantile Epilepsies

NCT01357707

Epilepsy Seizures, Infantile

COMPLETED

A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy

NCT03934268

Seizures Seizure Disorder Seizure Newborn +5 more

UNKNOWN

Molecular Genetic Mechanisms of Infantile Epilepsies and the Impact of Genetic Diagnosis

NCT06701084

Neonatal Epilepsy Infantile Epilepsy

RECRUITING NA

Pathophysiology Based Therapy of Early Onset Epileptic Encephalopathies

NCT02968966

Seizure, Epileptic

WITHDRAWN PHASE2

Association Between Ferroptosis and Epilepsy

NCT05269901

Epilepsy

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

According to estimates by the World Health Organization in 2019, more than 50 million people around the world have epilepsy. Nearly 80% of patients with epilepsy live in developing countries. In Vietnam, the incidence of epilepsy is approximately 40 per 100,000 per year. The incidence of the disease in children is higher than in adults. Among them, children under 2 years old are the group with the highest incidence of epilepsy, and at the same time, the most dangerous groups of epilepsy are also likely to start at these ages, such as West syndrome, Dravet syndrome, and Dravet syndrome. Ohtahara syndrome. These syndromes belong to the group of epileptic and developmental encephalopathies. This group of diseases can be caused by many causes, such as structural, metabolic, infectious, and genetic causes. However, in children and young people, genetic causes are more common.

Thanks to the development of biotechnology and genetics, medicine is now discovering more and more genes related to epilepsy syndromes that begin before 2 years of age, which helps choose treatment methods for the disease. causes of epilepsy such as using the keto diet in children with loss-of-function mutations in SLC2A1 or avoiding sodium channel blockers in children with Dravet syndrome due to loss-of-function mutations in SCN1A. In addition, children with epileptic and developmental encephalopathy due to genetic causes are also at higher risk of global developmental delay and autism spectrum disorders. Therefore, monitoring the progress of children with epileptic and developmental encephalopathy due to genetic causes plays an important role in early intervention, helping to improve disease prognosis.

World medical literature on epileptic encephalopathy and early-onset development before 2 years of age records that 71% of children have severe intellectual disability and 60% of children show signs of autism spectrum disorder, of which Children with epileptic and developmental encephalopathy due to genetic causes are at higher risk of developing neurodevelopmental disorders than children with epileptic and developmental encephalopathy due to other causes. In our country, there have been a number of studies on epileptic and developmental encephalopathy, as follows: A study conducted at Children's Hospital 2 showed the detection rate of gene mutations in patients with epileptic encephalopathy. menstruation and development is 38%, mainly SCN1A genotype mutation and Dravet syndrome phenotype. Another study that followed the short-term course of epileptic and developmental encephalopathy patients on the keto diet found that the majority of Dravet syndrome patients responded well to this treatment. However, studies in our country only describe genotypes and phenotypes separately without including progression, or only monitor the progression of phenotypes with treatment methods without paying attention to genotypes, or do not focus on focuses on studying the group of epileptic and developmental encephalopathies with onset before 2 years of age, which is the group with the highest incidence and most danger. Furthermore, most studies are cross-sectional or only monitor short-term progress. Therefore, the question is what is the phenotype, genotype, and progression after 2 years of follow-up of children with epileptic and developmental encephalopathy with onset before 2 years of age? We want to conduct this study to answer the above question.

Researching this issue will make an important contribution to a better understanding of the genotype, phenotype, and course of epileptic and developmental encephalopathies, thereby aiding the treatment and management of the disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy; Seizure Child Development Gene Abnormality Early Onset Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

early onset developmental epileptic encephalopathy

Select one that meets all 5 of the following criteria:

1. Diagnosed with EIDEE or EIMFS or ISS or SMEI or EMAS (according to ILAE's diagnostic criteria 2022)
2. Diagnosed with drug-resistant epilepsy according to ILAE 2010 criteria (according to ILAE's diagnostic criteria 2010)
3. Age at the start of participating in the study ranged from 0 to 23 months old
4. Relatives agree to participate in the research
5. There is no medical history of any diagnosis of hypoxic encephalopathy or inflammatory encephalopathy or traumatic encephalopathy or cerebral infarction or cerebral hemorrhage.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosed with Early infantile developmental and epileptic encephalopathy or Epilepsy of infancy with migrating focal seizures or infantile spasms syndrome or severe myoclonic epilepsy of infancy or Epilepsy with myoclonic-atonic seizures
2. Diagnosed with drug-resistant epilepsy according to ILAE 2010 criteria
3. Age at the start of participating in the study ranged from 0 to 23 months old
4. Relatives agree to participate in the research
5. There is no medical history of any diagnosis of hypoxic encephalopathy or inflammatory encephalopathy or traumatic encephalopathy or cerebral infarction or cerebral hemorrhage.